Disclosure of Erlotinib as a Multikinase Inhibitor in Pancreatic Ductal Adenocarcinoma

A placebo-controlled phase 3 trial demonstrated that the epidermal growth factor receptor (EGFR) inhibitor erlotinib in combination with gemcitabine was especially efficient in a pancreatic ductal adenocarcinoma (PDAC) subgroup of patients developing skin toxicity. However, EGFR expression was not p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Conradt, Laura, Godl, Klaus, Schaab, Christoph, Tebbe, Andreas, Eser, Stefan, Diersch, Sandra, Michalski, Christoph W, Kleeff, Jörg, Schnieke, Angelika, Schmid, Roland M, Saur, Dieter, Schneider, Günter
Formato: Artigo
Idioma:Inglês
Publicado em: Neoplasia Press Inc. 2011
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3223607/
https://ncbi.nlm.nih.gov/pubmed/22131878
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados